

Special Issue

Vaccination and Public Health Strategy

Message from the Guest Editors

Immunization is one of the most cost-effective health interventions. It prevents 3.5–5 million deaths and saves 2–3 million children from vaccine-preventable diseases every year. Ensuring the effective and sustainable implementation of all national immunization programs is crucial in order to achieve the Immunization Agenda 2030 vision of a “world where everyone, everywhere, at all ages fully benefits from vaccines for good health and well-being”.

We welcome original research articles, systematic reviews, and case studies that examine the challenges associated with introducing new vaccines, and welcome innovative approaches to financing and managing national immunization programs. Papers that discuss national strategies for vaccine procurement, supply chain management, and public–private partnerships that promote the sustainability of immunization are particularly encouraged.

This Special Issue provides an excellent opportunity for researchers and health professionals to share insights.

We look forward to receiving contributions that advance knowledge regarding vaccination and the strengthening of the health system in developing countries.

Guest Editors

Dr. Shenglan Tang
Dr. Lance E. Rodewald
Dr. Taufique Joarder

Deadline for manuscript submissions

30 June 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/230923

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).